MediciNova, Inc.
MNOVAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
| Date | Firm | Analyst | Target | Price Then | Source |
|---|---|---|---|---|---|
| Sep 17, 2026 | Roth Capital | Boobalan Pachaiyappan | $6.00(+138%) | $2.52 | TheFly |
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| D. Boral Capital | maintain | Buy | May 4, 2026 |
| D. Boral Capital | maintain | Buy | Jan 30, 2026 |
| D. Boral Capital | maintain | Buy | Dec 18, 2025 |
| D. Boral Capital | maintain | Buy | Dec 8, 2025 |
| D. Boral Capital | maintain | Buy | Nov 4, 2025 |
| D. Boral Capital | maintain | Buy | Oct 31, 2025 |
| D. Boral Capital | maintain | Buy | Sep 22, 2025 |
| D. Boral Capital | maintain | Buy | Aug 27, 2025 |
| D. Boral Capital | maintain | Buy | Jul 24, 2025 |
| B. Riley Securities | maintain | Buy | Jun 16, 2025 |
| D. Boral Capital | maintain | Buy | Apr 9, 2025 |
| D. Boral Capital | maintain | Buy | Mar 14, 2025 |
| D. Boral Capital | maintain | Buy | Feb 21, 2025 |
| D. Boral Capital | maintain | Buy | Dec 6, 2024 |
| B. Riley FBR | maintain | Buy | Mar 13, 2020 |
| B. Riley Securities | maintain | Buy | Mar 13, 2020 |
| Ladenburg Thalmann | maintain | Buy | May 24, 2012 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.06| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.05 | $-0.06 | $459.0K | $75.0K |
| May 15, 2026 | $-0.05 | $-0.06 | $187.0K | $187.0K |
| Feb 20, 2026 | $-0.06 | $-0.10 | $151.0K | — |
| Nov 13, 2025 | $-0.06 | $-0.08 | $61.5K | $151.7K |
| Aug 14, 2025 | $-0.07 | $-0.07 | $134.6K | $123.3K |
| May 14, 2025 | $-0.06 | $-0.14 | — | — |
| Feb 19, 2025 | $-0.06 | $-0.06 | — | — |
| Nov 14, 2024 | $-0.06 | $-0.06 | — | — |
News
CorMedix (NASDAQ: CRMD - Get Free Report) and MediciNova (NASDAQ: MNOV - Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, risk, institutional ownership, profitability, earnings, dividends and valuation. Valuation and Earnings This table compares CorMedix and MediciNova"s
MediciNova, Inc. (NASDAQ: MNOV - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have given a buy recommendation and one
MediciNova, Inc. (NASDAQ: MNOV - Get Free Report)'s stock price passed above its two hundred day moving average during trading on Tuesday. The stock has a two hundred day moving average of $1.51 and traded as high as $1.72. MediciNova shares last traded at $1.65, with a volume of 119,977 shares trading hands. Analyst Upgrades and
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that management will participate in the Maxim Growth Summit taking place October 12-14, 2026, at the Hard Rock Hotel New York. Management will be available for one-on-one meetings with investors registered for the event.
Merck KGaA (OTCMKTS:MKKGY - Get Free Report) and MediciNova (NASDAQ: MNOV - Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, institutional ownership, dividends, valuation and earnings. Valuation and Earnings This table compares Merck KGaA and
MediciNova Inc. (NASDAQ:MNOV) stock is trading lower on Monday after the company reported mixed topline results from its Phase 2 clinical trial evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus.
MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat MN-001 showed statistically significant increases in HDL-C and HDL-P and significant early reduction in triglyceride, a reduction in body weight and a numerical improvement in liver fat
LA JOLLA, Calif., Sept. 24, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the completion of the last patient, last visit (LPLV) in the double-blind portion of COMBAT-ALS, a Phase 2b/3 clinical trial evaluating MN-166 (ibudilast) for the treatment of Amyotrophic Lateral Sclerosis (ALS). A total of 234 participants were randomized to tw…
LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces that Yuichi Iwaki, M.D.
MediciNova (MNOV) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.07 per share a year ago.